Fig. 2: ctDNA-based MRD testing is predictive of survival outcomes in postsurgical patients with CRC.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
a, Kaplan–Meier estimates for DFS stratified by ctDNA-negative and ctDNA-positive status 4 weeks after surgery (pathological stages I–IV). HRs and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. 6M-DFS, 6-month DFS; 12M-DFS, 12-month DFS; 18M-DFS, 18-month DFS. b, Forest plot depicting the multivariate analysis for recurrence in patients with pathological stage II–III CRC. Various prognostic factors and their association with DFS, as indicated by HR, were analyzed across the cohort using the two-sided Wald chi-squared test. The unadjusted HRs (squares) and 95% CIs (horizontal lines) are shown for each prognostic factor. Vertical dotted line, the null hypothesis. Number of events = 102; global P value (log-rank) = 2.4188 × 10−27; Akaike information criterion = 1,183.72; concordance index = 0.81. c, Correlation between ctDNA status and CEA status 12 weeks after surgery.
